Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance

Batoul Farran; Samet Albayrak; Judith Abrams; Michael A. Tainsky; Nancy K. Levin; Robert Morris; Larry H. Matherly; Manohar Ratnam; Ira Winer

doi:10.1002/cam4.1944

Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance

Batoul Farran, Samet Albayrak, Judith Abrams, Michael A. Tainsky, Nancy K. Levin, Robert Morris, Larry H. Matherly, Manohar Ratnam, Ira Winer

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. This is also the first study to prospectively follow patients in the surveillance setting to concurrently identify differential changes in tumor markers CA-125 and sFR.

Original language	English (US)
Pages (from-to)	920-927
Number of pages	8
Journal	Cancer Medicine
Volume	8
Issue number	3
DOIs	https://doi.org/10.1002/cam4.1944
State	Published - Mar 2019
Externally published	Yes

Keywords

biomarkers
gynecologic oncology
translational research

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cam4.1944

Cite this

@article{2e17f8c8d7f04bbca41d68b32bb6ed04,

title = "Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance",

abstract = "Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. This is also the first study to prospectively follow patients in the surveillance setting to concurrently identify differential changes in tumor markers CA-125 and sFR.",

keywords = "biomarkers, gynecologic oncology, translational research",

author = "Batoul Farran and Samet Albayrak and Judith Abrams and Tainsky, {Michael A.} and Levin, {Nancy K.} and Robert Morris and Matherly, {Larry H.} and Manohar Ratnam and Ira Winer",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",

year = "2019",

month = mar,

doi = "10.1002/cam4.1944",

language = "English (US)",

volume = "8",

pages = "920--927",

journal = "Cancer Medicine",

issn = "2045-7634",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance

AU - Farran, Batoul

AU - Albayrak, Samet

AU - Abrams, Judith

AU - Tainsky, Michael A.

AU - Levin, Nancy K.

AU - Morris, Robert

AU - Matherly, Larry H.

AU - Ratnam, Manohar

AU - Winer, Ira

PY - 2019/3

Y1 - 2019/3

N2 - Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. This is also the first study to prospectively follow patients in the surveillance setting to concurrently identify differential changes in tumor markers CA-125 and sFR.

AB - Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. This is also the first study to prospectively follow patients in the surveillance setting to concurrently identify differential changes in tumor markers CA-125 and sFR.

KW - biomarkers

KW - gynecologic oncology

KW - translational research

UR - http://www.scopus.com/inward/record.url?scp=85063382723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063382723&partnerID=8YFLogxK

U2 - 10.1002/cam4.1944

DO - 10.1002/cam4.1944

M3 - Article

C2 - 30761774

AN - SCOPUS:85063382723

SN - 2045-7634

VL - 8

SP - 920

EP - 927

JO - Cancer Medicine

JF - Cancer Medicine

IS - 3

ER -

Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this